Pegcetacoplan shows increasing beneficial effects after 30 months of continuous treatment for GA
August 2nd 2023Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).
AOA 2023: The skinny on intravitreal injections for retinal diseases
June 22nd 2023Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.
ASCRS 2023: Risk factors for glaucoma after infantile cataract surgery
May 7th 2023In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.
ASCRS 2023: Negative effects of several contraceptive modalities on dry eye
May 7th 2023Lucie Moore, BSc, in a presentation at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, said the study focused on identifying factors that could put patients at a higher risk for developing dry eye disease.